Home > Cardiology > ACC 2022 > Heart Failure and Cardiomyopathy > Symptomatic obstructive hypertrophic cardiomyopathy: long-term mavacamten control

Symptomatic obstructive hypertrophic cardiomyopathy: long-term mavacamten control

Presented By
Prof. Florian Rader, Cedars-Sinai Medical Center, CA, USA
Conference
ACC 2022
Trial
MALVA-LTE
Mavacamten controlled symptomatic obstructive hypertrophic cardiomyopathy (HCM) for a median of 62 weeks and up to 84 weeks, with no additional safety concerns compared with the first 30 weeks on treatment, according to updated results from the EXPLORER-LTE cohort of the ongoing MALVA-LTE study. The MALVA-LTE (NCT03723655) trial is an international, ongoing, 5-year extension study including patients with symptomatic obstructive HCM who completed the treatment phase of the phase 3 MAVERICK-HCM (NCT03442764) and EXPLORER-HCM (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on